Apixaban and Aspirin: what is better?
Studies show, that an investigational drug called apixaban (Eliquis) seems to be better than aspirin at preventing blood clots in certain patients who have suffered a stroke or so-called "mini-stroke" due irregular heart rhythm.
Bristol-Myers Squibb and Pfizer which are developing apixaban, organized the study where they found that daily apixaban seems to be more effective at warding off a stroke or blood clot than aspirin.
To prove this fact, scientists from Canada and Germany, led by Dr. Hans-Christoph Diener of the University Hospital Essen, tracked nearly 5,600 atrial fibrillation patients (average age 70 years) for about one year.
The results have shown that among those taking apixaban who had a prior history of stroke or mini-stroke, only 2.4 percent went on to experience a subsequent stroke or systemic embolism (blood clot) during treatment. To compare to percentage among similar patients receiving daily aspirin it is higher on more than 9 percent. Researchers say that patients who took apixaban had no greater risk of major bleeding than those who took aspirin.
FDA is currently reviewing apixaban for approval.
Comments
(1)Thanks so much for giving everyone an extraordinarily breathtaking opportunity to read articles and blog posts from here. It's always so pleasing plus jam-packed with amusement for me personally and my office acquaintances to visit your website not less than thrice per week to study the newest things you have. And lastly, I'm just actually satisfied considering the eye-popping methods you give. Certain two ideas in this posting are surely the simplest we have all had.